Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer
Phase 4
18 Years
70 Years
18 Years
70 Years
Not Enrolling
Female
Locally Advanced Malignant Neoplasm
Female
Locally Advanced Malignant Neoplasm
Trial Information
Trial of Pemetrexed in Combined With Cisplatin for the Treatment of Advanced Breast Cancer
combination of pemetrexed and cisplatin to treat advanced breast cancer. Previous regimen no
more than 3 which including enthrycycline and taxanes(paclitaxel and/or docetaxel)
Inclusion Criteria:
- 18-70 years old
- Resistant to enthracycle and taxanes
- Has measurable disease
Exclusion Criteria:
- Has more than 3 previous chemotherapy regimens
Type of Study:
Interventional
Study Design:
Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
Outcome Measure:
PFS (progression free survival)
Outcome Time Frame:
2 Years
Safety Issue:
Yes
Principal Investigator
Binghe Xu, M.D.
Investigator Role:
Study Chair
Investigator Affiliation:
Chinese Academy of Medical Sciences
Authority:
China: Ministry of Health
Study ID:
CH-BC-008
NCT ID:
NCT01143974
Start Date:
June 2010
Completion Date:
June 2012
Related Keywords:
- Locally Advanced Malignant Neoplasm
- progress free survival
- response rate
- safety
- Breast Neoplasms
- Neoplasms
Name | Location |
|---|
